<DOC>
	<DOC>NCT02399137</DOC>
	<brief_summary>The purpose of this study is to determine whether the combination of MM-141 plus nab-paclitaxel and gemcitabine is more effective than nab-paclitaxel and gemcitabine alone based on Progression Free Survival (PFS) in front-line metastatic pancreatic cancer patients with high serum levels of free IGF-1.</brief_summary>
	<brief_title>A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>This is a randomized, double-blind, placebo-controlled Phase 2 study of MM-141 plus nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer. All patients will be initially screened for free IGF-1 status. Eligible patients with high free IGF-1 will be randomized to receive MM-141 plus nab-paclitaxel and gemcitabine or placebo plus nab-paclitaxel and gemcitabine and patients. Patients with low free IGF-1 or patients who have high free IGF-1 but are not otherwise eligible will be followed in an observational group.</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Metastatic adenocarcinoma of the pancreas. Patients with islet cell neoplasms are not eligible. Patient must have received no prior radiotherapy, surgery, chemotherapy, or investigational therapy for the treatment of metastatic disease. Blood sample sent for free IGF1 testing ECOG performance status (PS) of 0 or 1 Patients who only present with localized disease Patients with CNS malignancies (primary or metastatic) Clinically significant cardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Front-line Pancreatic Cancer</keyword>
	<keyword>Metastatic Pancreatic Cancer</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Nab-paclitaxel</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Free IGF-1</keyword>
	<keyword>Heregulin</keyword>
</DOC>